AbbVie submits sNDA to FDA for major depressive disorder therapy

cafead

Administrator
Staff member
  • cafead   Feb 23, 2022 at 10:22: AM
via Cariprazine is intended for the adjunctive treatment of MDD patients who are receiving ongoing antidepressant therapy. The company’s sNDA submission is based on data obtained from clinical trials

article source
 

<